POSIFLEX
16.1.2023 05:26:36 CET | Business Wire | Press release
As one of the world’s top five electronic Point of Sale (POS) system suppliers, Posiflex Technology is wrapping up a particularly banner year for 2022, benefiting from vigorous refurbishments in retail and hospitality industries during the post COVID-19 pandemic era. With excellent supply chain management and risk control, Posiflex has been less affected by the global supply crisis resulted from COVID-19 lockdowns and geographical conflicts on top of other risk factors during 2022, and the company is eyeing toward a further leap in its global-leading position.
World’s 5th Ranked POS Supplier Rises to the Challenge
According to the latest survey conducted by market intelligence firm RBR, Posiflex ranks as the 5th biggest POS brand in terms of shipped units throughout 2021, with its strongest presence in Southeast Asia, the Middle East, Africa and Europe. The RBR survey also found that Posiflex rose to 1st place in countries like India, the Philippines, Saudi Arabia and Greece, with its market share in India as high as 54%, and Saudi Arabia 42%.
Why Customers Choose Posiflex: Customization Capability, Quality and Delivery
A new customer feedback analysis conducted by RBR has revealed that Posiflex customers on a worldwide base are most satisfied with the company’s professional support including customization service, reliable quality, and stable delivery (effective and efficient logistics), ranking as the top 3 Posiflex advantages in the eyes of customers.
- Customization Service and better technical support
Posiflex is the only company among the top 5 POS suppliers to adopt a vertical integration strategy— it designs, manufactures, and sells POS systems and peripherals in-house, which means it is able to provide one-stop shopping service to customers as well as small volume customization to fit specific requirements of customers from different countries with various application scenarios and needs, including OS options, logo co-branding and special peripheral specs.
As Posiflex designs and manufactures products on its own, it is well-versed in technical details of its products and can be quicker and more helpful in responding to customers’ needs.
- Reliable quality
To provide reliable products, Posiflex takes care in selecting quality materials and conducts comprehensive tests before shipment, including vibration test, drop test, plus the industry’s highest standard full-system loading test in 40°C burn-in chamber for 12+ hours for all shipping products. Customers’ feedback also shows high satisfaction with Posiflex’s product quality.
- Good command of supply chain logistics
By merging various stages of production and supply chain into its own operations, Posiflex has also achieved better command of supply chain logistics with reduced need for outside entities. This, combined with a well-managed supplier network, has accumulated into better supply resilience for Posiflex to achieve more stable product deliveries and shorter delivery times than its competitors during the global supply shortage crisis in the past two years of the pandemic.
“Your success is our vision,” said Owen Chen, CEO of Posiflex, citing the company’s core values slogan. “We combine our technological advantages with customer needs and provide the most feasible products and services for partners and end users,” said Chen.
About POSIFLEX Group
Posiflex Group is a global leading Commercial Internet of Things (CIoT) enabler dedicated to providing O2O and embedded solutions. The group now is pillared by three business entities—Posiflex Technology, Portwell Inc. and US-based KIOSK Information Systems (KIS), specialized in the manufacturing of POS, embedded IPC and self-service kiosk respectively, with a common goal in pursuing a brave new world of smart commerce, where transactions become faster and more convenient physically or digitally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005378/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom